See more : Gladstone Capital Corporation – (GLADL) Income Statement Analysis – Financial Results
Complete financial analysis of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biohaven Pharmaceutical Holding Company Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Logistics Development Group plc (ESLGF) Income Statement Analysis – Financial Results
- Luyang Energy-Saving Materials Co., Ltd. (002088.SZ) Income Statement Analysis – Financial Results
- Stella-Jones Inc. (SJ.TO) Income Statement Analysis – Financial Results
- The Beauty Health Company (SKIN) Income Statement Analysis – Financial Results
- Lumi Gruppen AS (LUMI.OL) Income Statement Analysis – Financial Results
Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
About Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 462.51M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.37M | 1.39M | 91.66M | 72.00K | 0.00 | 0.00 |
| Gross Profit | -3.37M | -1.39M | 370.85M | -72.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 80.18% | 0.00% | 0.00% | 0.00% |
| Research & Development | 373.28M | 437.07M | 181.49M | 98.46M | 344.67M | 0.00 |
| General & Administrative | 56.90M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Selling & Marketing | 5.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 62.77M | 130.86M | 37.41M | 16.05M | 134.45M | 0.00 |
| Other Expenses | 0.00 | -1.91M | 1.21M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Cost & Expenses | 436.05M | 567.93M | 218.90M | 114.51M | 479.12M | 0.00 |
| Interest Income | 17.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | -12.71M | 0.00 |
| Depreciation & Amortization | 6.91M | 1.39M | 1.39M | 72.00K | 171.86K | 52.52K |
| EBITDA | -429.14M | -462.80M | -217.51M | -114.43M | -479.12M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | -47.03% | 0.00% | 0.00% | 0.00% |
| Operating Income | -436.05M | -567.93M | -218.90M | -114.51M | -479.12M | 0.00 |
| Operating Income Ratio | 0.00% | 0.00% | -47.33% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 26.50M | -1.91M | 6.47M | -4.16M | -49.26M | 0.00 |
| Income Before Tax | -409.55M | -569.84M | -212.43M | -118.67M | -528.39M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -45.93% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.38M | 438.00K | 1.37M | -134.30K | 419.00K | 0.00 |
| Net Income | -408.17M | -570.28M | -213.80M | -118.67M | -528.81M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | -46.23% | 0.00% | 0.00% | 0.00% |
| EPS | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| EPS Diluted | -5.73 | -12.75 | -5.97 | -3.31 | -10.91 | 0.00 |
| Weighted Avg Shares Out | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
| Weighted Avg Shares Out (Dil) | 71.20M | 44.74M | 35.82M | 35.82M | 48.49M | 0.00 |
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
The 3 Smartest Healthcare Stocks to Buy With $1K Right Now
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
Source: https://incomestatements.info
Category: Stock Reports